Pierre-Yves D.
- Country
- France
- Department
- Hématologie et thérapie cellulaire
Research Overview
- Phase I/II Evaluation of 177Lu-PentixaTher Radioligand Therapy in Relapsed/Refractory CXCR4-Positive Acute Leukemia
- Phase 1 Dose-Escalation Study of CC-96191 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
- Venetoclax Added to 3+7 and Midostaurin Induction in FLT3-Mutated Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
Data & Insights
Has run more than one trial at 110 of 285 partner sites.
Specializations
Acute Myeloid Leukemia
The investigator specializes in treating acute myeloid leukemia (AML), with particular emphasis on relapsed and refractory cases. Their research encompasses both newly diagnosed and treatment-resistant forms of the disease.
- FLT3-mutated AML treatment approaches
- Novel therapeutic combinations
- Advanced-stage leukemia management
Their work includes evaluation of targeted therapies and innovative treatment protocols for various AML subtypes.
Hematologic Malignancies
The investigator focuses on developing treatments for various blood cancers, including chronic myelomonocytic leukemia (CMML) and other advanced hematologic conditions.
- Targeted molecular inhibitors
- Immunotherapy applications
- Combination therapy strategies
Their research extends to innovative therapeutic approaches for treatment-resistant blood cancers.
Novel Therapeutic Approaches
The investigator explores cutting-edge treatment modalities including radioligand therapy and targeted molecular therapies for leukemia patients.
- Experimental drug development
- Therapeutic resistance mechanisms
- Treatment optimization strategies
Their work incorporates both monotherapy and combination approaches for improved patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.